



OPEN

## Substitution of I222L-E119V in neuraminidase from highly pathogenic avian influenza H7N9 virus exhibited synergistic resistance effect to oseltamivir in mice

Jing Tang, Rongbao Gao, Liqi Liu, Shuxia Zhang, Jia Liu, Xiyan Li, Qionqiong Fang, Zhaomin Feng, Cuiling Xu, Weijuan Huang & Dayan Wang

That the high frequency and good replication capacity of strains with reduced susceptibility to neuraminidase inhibitors (NAIs) in highly pathogenic avian influenza H7N9 (HPAI H7N9) virus made it a significance to further study its drug resistance. HPAI H7N9 viruses bearing NA I222L or E119V substitution and two mutations of I222L-E119V as well as their NAIs-sensitive counterpart were generated by reverse genetics for NA inhibition test and replication capability evaluation *in vitro*. The attenuated H7N9/PR8 recombinant viruses were developed to study the pathogenicity and drug resistance brought by the above substitutions to mice. The  $IC_{50}$  fold change of oseltamivir to HPAI H7N9 with NA222L-119V is 306.34 times than that of its susceptible strain, and 3.5 times than the E119V mutant virus. HPAI H7N9 bearing NA222L-119V had good replication ability with peak value of more than  $6\log_{10}$  TCID<sub>50</sub>/ml in MDCK cells. H7N9/PR8 virus bearing NA222L-119V substitutions led to diffuse pneumonia, significant weight loss and fatality in mice. NA E119V made H7N9/PR8 virus resistant to oseltamivir, and I222L-E119V had synergistic resistance to oseltamivir in mice. Due to the good fitness of drug resistant strains of HPAI H7N9 virus, it is necessary to strengthen drug resistance surveillance and new drug research.

Human infection with highly pathogenic avian influenza (HPAI) H7N9 virus appeared at the end of 2016 and re-emerged at 2019<sup>1-3</sup>. As the mutant of H7N9, HPAI H7N9 virus is characterized by the insertion of polybasic amino acids at the cleavage of its hemagglutinin (HA) protein<sup>4,5</sup>. Although the mortality of HPAI H7N9 virus in laboratory confirmed human cases is not significantly higher to that of its low pathogenic (to birds) counterpart, the former seems to have a shorter course of disease and more severe clinical symptoms<sup>6</sup>.

Neuraminidase inhibitors (NAIs) are the only way to treat influenza infection in most countries in the world currently<sup>7</sup>. The approved NAIs in China, included oseltamivir, zanamivir and peramivir, and most H7N9 patients received oseltamivir<sup>1,8-10</sup>. Laninamivir, as well as the polymerase inhibitor baloxavir marboxil, which were recently approved by some countries/areas, are possible antiviral options against influenza infection<sup>11-13</sup>. Due to the poor error correction ability of the single stranded RNA virus<sup>14</sup>, influenza virus is prone to adaptive mutation for survival<sup>15</sup>. Early use of appropriate NAIs can prevent mice infected with lethal dose of H7N9 virus from severe weight loss and death<sup>16</sup>. However, amino acid mutation at the key site of neuraminidase (NA) may lead to reduced susceptibility of influenza virus to NAIs and thus weaken the therapeutic effect<sup>17</sup>. There are 19 highly conserved residues in the NA active site of all influenza A and B viruses. These include eight catalytic residues (R118, D151, R152, R224, E276, R292, R371, and Y406) that directly contact the sialic acid (SA) and 11 framework residues (E119, R156, W178, S179, D198, I222, E227, H274, E277, N294, and E425) that support the enzymatic binding pocket<sup>18,19</sup>. When the conserved amino acids in the NA active site of influenza virus mutated,

National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention; WHO Collaborating Center for Reference and Research on Influenza, No.155 Changbai Road, Changping District, Beijing, China. email: dayanwang@cnic.org.cn

Viruses	Oseltamivir		Zanamivir		Peramivir		Laninamivir	
	Mean IC <sub>50</sub> <sup>a</sup> (nM) ± SD	Fold change <sup>b</sup>	Mean IC <sub>50</sub> <sup>a</sup> (nM) ± SD	Fold change <sup>b</sup>	Mean IC <sub>50</sub> <sup>a</sup> (nM) ± SD	Fold change <sup>b</sup>	Mean IC <sub>50</sub> <sup>a</sup> (nM) ± SD	Fold change <sup>b</sup>
rg006NA(222I-119E)	1.61 ± 0.04	1.00	1.93 ± 0.09	1.00	0.28 ± 0.02	1.00	0.72 ± 0.04	1.00
rg006NA119V	141.73 ± 10.52	88.03 <sup>c</sup>	11.81 ± 0.32	6.12	0.48 ± 0.01	1.71	3.26 ± 0.02	4.53
rg006NA222L	7.25 ± 0.79	4.50	4.75 ± 0.38	2.46	0.28 ± 0.02	1.00	1.23 ± 0.06	1.71
rg006NA222L-119V	493.20 ± 29.10	306.34 <sup>c</sup>	14.53 ± 1.25	7.53	0.52 ± 0.01	1.86	3.14 ± 0.04	4.36

**Table 1.** Susceptibility of mutant recombinant highly pathogenic H7N9 avian influenza virus to neuraminidase inhibitors. <sup>a</sup>IC<sub>50</sub>, half-maximal inhibitory concentration. The IC<sub>50</sub> denotes the concentration of a NA inhibitor that reduces the NA activity by 50% relative to NA activity without the inhibitor. <sup>b</sup>Fold change relative to the mean IC<sub>50</sub> of the wild-type NA protein. Fold-change values of each NA were interpreted using criteria established by the World Health Organization Influenza Antiviral Working Group. <sup>c</sup>Fold change >10 (including reduced/highly reduced inhibition).

the susceptibility to NAIs may be reduced. NA R292K substitution could lead to resistance among multiple NA subtypes of influenza virus, but other resistance mutation sites may be subtype-specific<sup>20,21</sup>. Recombinant N9 proteins bearing substitutions showed that R292K, H274Y conferred high increase in oseltamivir half-maximal inhibitory concentration (IC<sub>50</sub>), and E119D conferred high zanamivir IC<sub>50</sub>. Additionally, R152Kof A (H7N9) virus conferred reduced inhibition by laninamivir<sup>22</sup>.

Our previous research found that the rate of strains isolated from human with reduced susceptibility to NAIs in HPAI H7N9 virus was high<sup>23</sup>. HPAI H7N9 viruses with reduced susceptibility to neuraminidase inhibitors (NA R292K, E119V or H274Y) showed good replication capacity in mammalian cells<sup>24</sup>. Interestingly, NA 119V or D substitutions in HPAI H7N9 showed reduced susceptibility to oseltamivir and zanamivir respectively<sup>24</sup>. Like E119 amino acids, I222 amino acids are also located in the frame region of NA, and it has been reported that I222 substitutions combined with other frame region resistance sites have been detected in seasonal influenza cases<sup>25,26</sup>. In this study, we want to test if the two framework mutations (E119V and I222L) of NA could coexist in HPAI H7N9 virus, and study its effect on viral fitness and drug resistance effect in mammalian cells and mice.

## Results


**Generation of recombinant viruses.** In this study, A/Guangdong/17SF006/2017 (H7N9) was used as a backbone. The NAIs-sensitive HPAI H7N9 virus constructed by reverse genetics containing NA 119E, 222I, was called rg006NA. The HPAI H7N9 reassortment viruses bearing substitutions were called rg006NA119V, rg006NA222L and rg006NA222L-119V according to their mutations.

The H7N9/PR8 reassortment virus and its NA mutants were called rg006NA/PR8, rg006NA119V/PR8, rg006NA222L/PR8 and rg006NA222L-119V/PR8 respectively. The sequencing of H7N9/PR8 recombinant viruses showed that 339–342KRTA polybasic amino acids in HA had been knocked out correctly, and all the six internal genes were from PR8. The four recombinant H7N9/PR8 viruses of rg006NA/PR8, rg006NA119V/PR8, rg006NA222L/PR8 and rg006NA222L-119V/PR8 were cultured at 35 °C for 48 h at a dilution of 10<sup>-1</sup>–10<sup>-6</sup>, and none were lethal to 9–11 day embryonated chicken eggs. The results of trypsin dependence test showed that all the four H7N9/PR8 recombinant viruses could not replicate without TPCK-trypsin, suggesting that the virus was dependent on TPCK-trypsin. The results showed that the recombinant H7N9/PR8 virus was attenuated successfully.

The recombinant viruses used in this study were confirmed by sequencing and listed in Supplementary Table S1.

**Assessment of susceptibility to neuraminidase inhibitors.** The susceptibility of HPAI H7N9 reassortment viruses to NAIs was assessed (Table 1). The substitution of E119V in the NA protein induced a mean 88.03-fold and 6.12-fold increase in the IC<sub>50</sub> of oseltamivir (mean IC<sub>50</sub> (nM) ± SD, 141.73 ± 10.52) and zanamivir (mean IC<sub>50</sub> (nM) ± SD, 11.81 ± 0.32) respectively. The IC<sub>50</sub> fold change of oseltamivir or zanamivir to rg006NA222L were 4.50 and 2.46 times respectively, which did not meet the phenotype resistance standard. However, when I222L and E119V substitutions coexist in the NA protein of HPAI H7N9 virus, the IC<sub>50</sub> fold change of oseltamivir to rg006NA222L-119V is 306.34 (mean IC<sub>50</sub> (nM) ± SD, 493.20 ± 29.10) times than that of its susceptible strain, and 3.5 times than that of the E119V single point mutant virus. The result showed that NA I222L-E119V substitutions had synergistic resistance effect to oseltamivir for HPAI H7N9 virus. On the other hand, rg006NA222L-119V induced a mean 7.53-fold increase in the IC<sub>50</sub> of zanamivir, which is similar to the value of E119V single point mutant virus. Besides, the fold change of IC<sub>50</sub> value of all the three mutant viruses to peramivir and laninamivir was less than 10, suggesting normal inhibition.

**Growth characteristics of mutant viruses in MDCK cells.** To test the effect of the NAIs resistance mutations on the growth characteristics of the HPAI H7N9 virus, we determined infectious titers in MDCK cells. MDCK cells were infected with rg006NA, rg006NA119V, rg006NA222L and rg006NA222L-119V virus by 0.001 MOI. At time points 0, 18, 24, 48, 72 and 96hpi, viral titers were determined on MDCK cells. Rg006NA and rg006NA119V virus showed similar replication level in MDCK cells at different time points (*P* > 0.05) (Fig. 1).



**Figure 1.** Replication kinetics of mutant recombinant highly pathogenic H7N9 avian influenza viruses in MDCK cells. Cells were inoculated with the recombinant viruses at 37 °C, and culture supernatants were harvested at 0, 18, 24, 48, 72 and 96 h post-inoculation (hpi). Virus titers were determined on MDCK cells. Growth curve of rg006NA in MDCK cells was in blue, round; rg006NA119V virus was in red, square; rg006NA222L virus was in orange, triangle; rg006NA222L-119V virus was in black, triangle. Each data point represents the mean  $\log_{10} \pm$  SD TCID<sub>50</sub>/ml from at least two independent tests. #*P* < 0.05. \**P* < 0.05.

The replication level of rg006NA222L was lower than that of rg006NA in 18 and 24 hpi (#*P* < 0.05), but they showed similar replication level after 48 hpi in MDCK cells. Replication peak value of rg006NA222L-119V reached more than 6log<sub>10</sub> TCID<sub>50</sub>/ml in 48 h although its replication level was lower than that of rg006NA(\**P* < 0.05). The results showed that rg006NA222L-119V, the two sites mutant virus with synergistic drug resistance effect to NAIs, had good replication ability in mammalian cells though lower than that of the sensitive strain.


**Pathogenicity in mice.** The body weight curve and survival condition of 8-week-old female C57 mice infected with 10<sup>1</sup>–10<sup>6</sup> TCID<sub>50</sub> recombinant H7N9/PR8 viruses are shown in Fig. 2. When infection at a lower dose ( $\leq 10^4$  TCID<sub>50</sub>), all mice infected with these four strains survived except one mouse in the 10<sup>4</sup> TCID<sub>50</sub> rg006NA222L/PR8 group (Fig. 2A–D). Rg006NA119V-222L/PR8 viruses showed no obvious weight loss at lower dose ( $\leq 10^4$  TCID<sub>50</sub>) (Fig. 2A–D). However, when the infection dose reached 10<sup>5</sup>–10<sup>6</sup> TCID<sub>50</sub>, all the four viruses could lead to significant weight loss and fatality in mice (Fig. 2E,F). There was no significant difference in the survival day of mice among the four viruses from 10<sup>1</sup> TCID<sub>50</sub>–10<sup>6</sup> TCID<sub>50</sub> (*P* > 0.05). There was no significant difference of hazard ratio between the mutant virus (rg006NA119V/rg006NA222L/PR8/rg006NA119V-222L/PR8) and rg006NA/PR8 (*P* > 0.05). The survival ratio of rg006NA222L-119V/PR8 virus at 10<sup>5</sup>–10<sup>6</sup> TCID<sub>50</sub> was 0% (the same as rg006NA222L/PR8), which was even lower than that of rg006NA (10<sup>5</sup> TCID<sub>50</sub>: 40%; 10<sup>6</sup> TCID<sub>50</sub>: 20%) and rg006NA119V (10<sup>5</sup> TCID<sub>50</sub>: 20%; 10<sup>6</sup> TCID<sub>50</sub>: 20%) (Table 2).

The mouse lethal dose of 50% animals (MLD<sub>50</sub>) of rg006NA/PR8, rg006NA119V/PR8, rg006NA222L/PR8 and rg006NA222L-119V/PR8 virus to C57 mice was 10<sup>5</sup> TCID<sub>50</sub>, 10<sup>4.75</sup> TCID<sub>50</sub>, 10<sup>4.38</sup> TCID<sub>50</sub> and 10<sup>4.5</sup> TCID<sub>50</sub>, respectively.

The viral load of rg006NA/PR8, rg006NA119V/PR8, rg006NA222L/PR8 and rg006NA222L-119V/PR8 in the respiratory tract of mice were shown in Fig. 3. ANOVA test was used to analyze the difference of viral load of the 4 strains in different tissues (lung and trachea) at different time points (1, 3, 5, 7, 14 dpi) and the result showed that there was no significant difference among the 4 viruses (*P* > 0.05) except that in lung tissue 1dpi (#*P* < 0.05) of the 10<sup>5</sup> TCID<sub>50</sub> group (Fig. 3B). When administered with 10<sup>4</sup> TCID<sub>50</sub> of the 4 viruses, the viral load in trachea of the mice infected with rg006NA/PR8 and rg006NA222L-119V/PR8 was higher at 3dpi than that at 1dpi (\**P* < 0.05), which indicated viral replication, and on 5dpi, no viral load was detected in trachea. When administered with 10<sup>5</sup> TCID<sub>50</sub>, the viral load in trachea of the mice decreased from 1 to 3 dpi, and on 5dpi it could only be detected in one mouse in the rg006NA222L-119V/PR8 and the rg006NA222L/PR8 group respectively. And on 7 dpi, no viral load was detected in trachea of all the mice. When administered with 10<sup>4</sup> TCID<sub>50</sub> or 10<sup>5</sup> TCID<sub>50</sub> of the 4 viruses, the viral load in lungs of mice was high at 1 dpi and 3 dpi, and then decreased from 5 dpi. On 7 dpi, viral load in lung could only be detected in one mouse infected with rg006NA/PR8, rg006NA222L/PR8 or rg006NA222L-119V/PR8 virus in the 10<sup>5</sup> TCID<sub>50</sub> dose group respectively. On 14 dpi, no virus load was detected in lungs of all the mice. In general, the viral load in the respiratory tract of mice infected with rg006NA/PR8, rg006NA119V/PR8, rg006NA222L/PR8 and rg006NA222L-119V/PR8 virus bore out similar trend.

Through the detection of HA antibody in mouse serum (serum antibody titer shown in Supplementary Table S2), we calculated that the mouse infective dose of 50% animals (MID<sub>50</sub>) of rg006NA/PR8, rg006NA119V/PR8, rg006NA222L/PR8 and rg006NA222L-119V/PR8 was 0.83 TCID<sub>50</sub>, 1 TCID<sub>50</sub>, 0.83 TCID<sub>50</sub> and 1.38 TCID<sub>50</sub> respectively. The results showed that the infectivity of the four viruses to mice was similar and all of them can infect mice at a low dose.


Lungs of mice infected with 10<sup>4</sup> and 10<sup>5</sup> TCID<sub>50</sub> viruses on 3dpi were studied for pathology. In Fig. 4A, the lung tissue of PBS control group of mice showed normal shape without obvious change. The lung tissues infected with the 4 viruses showed inflammatory cell infiltration, alveolar injury and other pathological changes. At 10<sup>4</sup> TCID<sub>50</sub>, there were some inflammatory cells in lung tissues of mice infected with the four viruses. At 10<sup>5</sup> TCID<sub>50</sub>, all the lung tissues infected with the 4 viruses exhibited much inflammatory infiltration and extensive pneumonia.



**Figure 2.** Body weight curve and survival condition of mice infected with different doses of H7N9/PR8 recombinant viruses. Body weight change and survival condition of C57BL/6 mice (n = 5/group) inoculated intranasal with  $10^1$ – $10^6$  TCID<sub>50</sub> recombinant H7N9/PR8 viruses. Control group: PBS. (A)  $10^1$  TCID<sub>50</sub>; (B)  $10^2$  TCID<sub>50</sub>; (C)  $10^3$  TCID<sub>50</sub>; (D)  $10^4$  TCID<sub>50</sub>; (E)  $10^5$  TCID<sub>50</sub>; (F)  $10^6$  TCID<sub>50</sub>.

Virus dose (TCID <sub>50</sub> )	rg006NA			rg006NA119V				rg006NA222L				rg006NA222L-119V			
	No. of mice survived/ total no.	Survival rate (%)	Mean survival day	No. of mice survived/ total no.	Survival rate (%)	Mean survival day	Hazard ratio <sup>a</sup>	No. of mice survived/ total no.	Survival rate (%)	Mean survival day	Hazard ratio <sup>b</sup>	No. of mice survived/ total No	Survival rate (%)	Mean survival day	Hazard ratio <sup>c</sup>
$10^1$	5/5	100	14 ± 0	5/5	100	14 ± 0	1	5/5	100	14 ± 0	1	5/5	100	14 ± 0	1
$10^2$	5/5	100	14 ± 0	5/5	100	14 ± 0	1	5/5	100	14 ± 0	1	5/5	100	14 ± 0	1
$10^3$	5/5	100	14 ± 0	5/5	100	14 ± 0	1	5/5	100	14 ± 0	1	5/5	100	14 ± 0	1
$10^4$	5/5	100	14 ± 0	5/5	100	14 ± 0	1	5/5	80	12 ± 4	65.29, 95% CI 0–6.28e8	4/5	100	14 ± 0	1
$10^5$	2/5	40	7 ± 5	1/5	20	6 ± 4	1.19, 95% CI 0.27–5.35	0/5	0	4 ± 0	1.44, 95% CI 0.34–6.06	0/5	0	3 ± 0	1.67, 95% CI 0.40–6.97
$10^6$	1/5	20	4 ± 1	1/5	20	5 ± 4	2.24, 95% CI 0.51–9.75	0/5	0	3 ± 0	1.95, 95% CI 0.46–8.21	0/5	0	3 ± 0	2.24, 95% CI 0.51–9.75

**Table 2.** Pathogenicity of the reassortment H7N9/PR8 influenza viruses in a C57 mouse model. <sup>a</sup>rg006-NA119V vs rg006-NA, Cox regression analysis by SPSS software. <sup>b</sup>rg006-NA222L vs rg006-NA, Cox regression analysis by SPSS software. <sup>c</sup>rg006-NA222L-119V vs rg006-NA, Cox regression analysis by SPSS software.




**Figure 3.** Replication of H7N9/PR8 recombinant viruses in the respiratory tract of mice. C57BL/6 mice ( $n=3$ /time-point) were inoculated intranasal with  $10^4$  TCID<sub>50</sub> (A) or  $10^5$  TCID<sub>50</sub> (B) of the H7N9/PR8 recombinant viruses. Mice were euthanized at 1, 3, 5, 7 and 14 dpi. Viral titers in the lung (lu) or tracts (tr) were determined on MDCK cells. \* $P < 0.05$ . # $P < 0.05$ .

Immunohistochemistry results shown in Fig. 4B, there is no NP antigen distribution in the lung tissue of PBS control group mice. After  $10^4$  TCID<sub>50</sub> doses of infection, the lung tissues infected with the 4 viruses were stained with scattered NP antigens. A large number of NP antigens were found in lung tissues infected with the 4 viruses when infected with  $10^5$  TCID<sub>50</sub>, which were widely distributed.

In conclusion, rg006NA/PR8, rg006NA119V/PR8, rg006NA222L/PR8 and rg006NA222L-119 V/PR8 viruses had similar pathogenicity to mice.

**Synergistic resistance to oseltamivir in mice.** We infected mice with 2MLD<sub>50</sub> of the 4 viruses. As shown in Fig. 5, administrated with oseltamivir 20 mg/kg/day by gavage could prevent rg006NA/PR8 or rg006NA222L/PR8 infected mice from much body weight loss and fatality (Fig. 5A,B,E,F). The survival day of rg006NA/PR8 and rg006NA222L/PR8 infected mice given oseltamivir treatment was longer than their non-treatment counterparts (\* $P < 0.05$ ). There was no statistical difference between the survival day of rg006NA119V/PR8 and rg006NA222L-119V/PR8 infected mice in oseltamivir or non-treatment group ( $P > 0.05$ ). There was no significant difference of hazard ratio between the oseltamivir-treated and non-treated group of all the four viruses ( $P > 0.05$ ) (Table 3). The rg006NA119V/PR8 infected mice by oseltamivir administration had a slight alleviation of body weight loss and fatality compared with the non-medication group (Fig. 5C,D). However, the rg006NA222L-119V/PR8 infected mice got the resemble body weight loss no matter whether or not to give oseltamivir treatment (Fig. 5G). The mortality rate of rg006NA222L-119 V/PR8 mice with or without drug administration was 60% and 80% respectively (Fig. 5H). The results showed that oseltamivir had poor therapeutic effect on rg006NA119V/PR8 and even poorer therapeutic effect on rg006NA222L-119V/PR8 virus, which could not effectively protect mice from weight loss and death.


The viral load of rg006NA/PR8, rg006NA119V/PR8, rg006NA222L/PR8 and rg006NA222L-119V/PR8 in lungs of mice with oseltamivir administration are shown in Fig. 6. The rg006NA/PR8 infected mice had significantly lower viral load in lung by oseltamivir administrated than the non-medication group (2, 4 and 6 dpi,  $P < 0.05$ , Fig. 6A). There is no difference of viral load in lung between the treated and the non-treated mice which infected with rg006NA119V/PR8 or rg006NA222L/PR8 until 6 dpi ( $P < 0.05$ , Fig. 6B, C). Mice infected with



**Figure 4.** Pathological changes of lung tissue in mice infected with H7N9/PR8 recombinant viruses. The lung tissues of mice infected with  $10^4$ – $10^5$  TCID<sub>50</sub> H7N9/PR8 recombinant viruses were stained by hematoxylin and eosin ((A) HE  $\times 20$ ) and NP antigen ((B) IHC  $\times 20$ ) 3 days after infection. Control group: PBS.

rg006NA222L-119V/PR8 virus had similar viral load in lung at 2, 4 and 6 dpi no matter whether given oseltamivir or not (Fig. 6D). At 2 and 4 days of oseltamivir administration, the viral load of rg006NA119V/PR8 infected mice was higher than the rg006NA/PR8 group ( $P < 0.05$ , Fig. 6E). At 6 days of oseltamivir administration, the viral load of rg006NA222L-119V/PR8 infected mice was higher than the rg006NA/PR8, rg006NA119V/PR8 or rg006NA222L/PR8 group ( $P < 0.05$ , Fig. 6E).

Four days after infection, lungs of rg006NA/PR8, rg006NA119V/PR8, rg006NA222L/PR8 and rg006NA222L-119V/PR8 infected mice with oseltamivir administration were taken for pathological observation. By HE staining (Fig. 7A), without medication, mice infected with the four viruses all developed diffuse pneumonia with a large number of inflammatory cell infiltration. Under the condition of oseltamivir, only a small number of



**Figure 5.** Body weight curve and survival condition of mice infected with H7N9/PR8 recombinant viruses treated with oseltamivir phosphate. The C57 mice were infected with 2MLD<sub>50</sub> rg006NA/PR8, rg006NA119V/PR8, rg006NA222L-119V/PR8 and rg006NA222L/PR8 (n = 5/group). The mice in the drug treatment group were given 20 mg/kg/day oseltamivir phosphate by gavage from 0 to 4 dpi, and the mice in the non-drug group were given PBS by gavage from 0 to 4 dpi. On the day of infection, the mice in the control group were given PBS, and then the mice were given 20 mg/kg/day oseltamivir phosphate by gavage. (A,C,E,G) weight curve of mice; (B,D,F,H) survival condition of mice. (A,B) rg006NA/PR8; (C,D) rg006NA119V/PR8; (E,F) rg006NA222L/PR8; (G,H) rg006NA222L-119V/PR8.

	rg006NA/PR8		rg006NA119V/PR8		rg006NA222L/PR8		rg006NA222L-119V/PR8	
	PBS	Oseltamivir	PBS	Oseltamivir	PBS	Oseltamivir	PBS	Oseltamivir
No. of mice survived	1/5	5/5	1/5	3/5	1/5	5/5	1/5	2/5
Survival rate	20%	100%	20%	60%	20%	100%	20%	40%
Mean survival days	5 ± 4*	14 ± 0*	6 ± 4	10 ± 5	6 ± 4*	14 ± 0*	6 ± 4	8 ± 5
Hazard ratio	0.02, 95% CI 0–47.51		0.42, 95%CI 0.08–2.31		0.01, 95% CI 0–40.07		0.64, 95% CI 0.14–2.85	

**Table 3.** Survival of mice in drug or non-drug groups. \* $P < 0.05$ .

inflammatory cells were found in the lung of rg006NA/PR8 infected mice which was obviously milder inflammatory than the non-drug group. As to rg006NA222L/PR8 virus, after drug treatment, the pathological changes of lung in mice were significantly alleviated. However, there was no significant difference in lung pathological damage between the oseltamivir-treated and non-treated mice which infected with rg006NA119V/PR8 and rg006NA222L-119V/PR8 virus. As a PBS control group, oseltamivir by gavage made no obvious pathological changes in the lung tissue of mice.

The distribution of NP antigen was consistent with the above result, that the use of oseltamivir reduced the lung antigens in mice infected with rg006NA/PR8 and rg006NA222L/PR8 (Fig. 7B), but did not significantly reduce the antigens in mice infected with rg006NA119V/PR8 and rg006NA222L-119V/PR8. As a PBS control group, there is no antigen in the lung tissue of mice.

In all, E119V substitution in NA made the H7N9/PR8 reassortment virus resistant to oseltamivir in mice. What's more, NA substitutions of I222L and E119V had synergistic resistance effect on the H7N9/PR8 reassortment virus to oseltamivir in mice.

## Discussion


Generally, when influenza viruses possess drug resistant mutations, their replication level in cells or their pathogenicity to animals may be reduced to varying degrees, especially when mutations occur in catalytic residues that directly contact the sialic acid (SA)<sup>19,27</sup>. After a single site mutation of R292K, the enzyme activity of HPAI H7N9 virus decreased significantly and its replication ability decreased to some extent<sup>19</sup>. According to the substitution with reduced susceptibility to NAIs detected in HPAI H7N9 cases<sup>24</sup>, we used reverse genetic technology to develop double sites mutant HPAI H7N9 viruses carrying I222L-119V, H274Y-R292K and E119V-R292K, but only the enzyme activity of rg006NA222L-119V virus was enough to perform the NA inhibition test.

Seasonal influenza viruses bearing two mutations in the frame region of NA had been reported before. A H3N2 virus possessing the mutations E119V-I222V, isolated from human cases and induced a synergistic effect on oseltamivir resistance test in vitro<sup>26</sup>. Besides, prophylactic treatment with oseltamivir had failed in two H1N1 with H274Y-I222M mutations infected patients<sup>25</sup>. These results show that the two site mutations in the framework region can coexist in influenza viruses, and some of them have synergistic drug resistance effect. However, these studies are limited to clinical discovery or cell level studies of seasonal influenza viruses, and there are few studies of influenza virus with double resistance sites in a mouse model.

The E119 residue is conserved among all influenza A viruses and forms a hydrogen bond with the hydroxyl group on the C-4 of sialic acid<sup>28</sup> and with the amino group on C-4 of oseltamivir<sup>29</sup>. E119A/D/G/I/V substitutions have been examined conferring resistance to NAIs in influenza viruses of various subtypes<sup>22,24,30–34</sup>. And in this study, E119V substitution in HPAI H7N9 virus induced a mean 88.03-fold increase in the IC<sub>50</sub> of oseltamivir. The I222 residue is a conserved residue in NA of influenza viruses and I222V/M/L/R/T substitutions had been reported with the N1, N2, and B backgrounds conferring moderate resistance to oseltamivir<sup>31,33–36</sup>. However, NA I222L substitution of HPAI H7N9 did not lead to drug resistance to oseltamivir, zanamivir, peramivir and laninamivir according to WHO-AVWG criteria. In this study, the two mutations of E119V-I222L were chosen to study the synergistic drug resistance of HPAI H7N9 virus in mice. The IC<sub>50</sub> fold change of oseltamivir to rg006NA222L-119V is 306.34 times than that of its susceptible strain, and 3.5 times than that of the E119V single point mutant virus, which showed synergistic resistance effect. A crystal structure model of the NA monomer of the A/Anhui/1/2013 H7N9 virus (PDB ID: 4MWJ) was used to display and label the two mutations (E119V and I222L) in H7N9 virus (seen in Supplementary Fig. S1). Both 119V and 222L which located around the catalytic sites of NA were framework sites that interact with catalytic residues to stabilize the active site.


NAIs development is structure-based drug design<sup>37</sup>. As a surface glycoprotein with enzyme activity, NA is an ideal target for the design of competitive inhibitors<sup>38</sup>. NAIs bind to the NA active site with a higher affinity than the natural SA and prevent the release of new virions from infected cells<sup>39</sup>. Oseltamivir (oseltamivir phosphate) is taken orally and then converted to its active form (oseltamivir carboxylate) to disseminate systemically. The recommended oral dose for adolescents and adults is 75 mg oseltamivir twice daily for 5 days<sup>40</sup>. Excessive concentration of oseltamivir is not conducive to antiviral treatment<sup>16,41–43</sup>. The concentration of oseltamivir selected in this study is 20 mg/kg/day, which is feasible and effective in this study. Consistent with the result of NA inhibition test in vitro, E119V-I222L in N9 from HPAI H7N9 virus have synergistic drug resistance effect to oseltamivir in mice (Figs. 5, 6). When infected at 10<sup>4</sup> TCID<sub>50</sub>, the pathogenicity of the rg006NA222L-119V/PR8 virus to mice is slightly lower (less weight loss) compared with rg006NA119V/PR8, rg006NA222L/PR8 and their sensitive strain (Fig. 2D), which is basically the same as that on MDCK cells (Fig. 1). Significantly, when the infection dose reached 10<sup>5</sup>–10<sup>6</sup> TCID<sub>50</sub>, rg006NA222L-119V/PR8 (and rg006NA222L/PR8) virus even lead to more weight loss and fatality rate than that of rg006NA/PR8 and rg006NA119V/PR8 in mice (Fig. 2E,F). It





**Figure 6.** Viral load of lung tissue of mice infected with H7N9/PR8 recombinant viruses treated with oseltamivir phosphate. The lung tissues of C57 mice infected with 2MLD<sub>50</sub> H7N9/PR8 recombinant viruses were titrated 2, 4 and 6 dpi (n = 3/time-point). Mice in the drug treatment group: 20 mg/kg/day oseltamivir phosphate by gavage from 0 to 4dpi; Mice in the non-drug group: PBS by gavage from 0 to 4 dpi. (A–D) Comparison of mice infected with H7N9/PR8 recombinant viruses in the drug treatment group or non-drug group. (E) Comparison of mice infected with rg006NA/PR8 (NA), rg006NA119V/PR8 (119V) and rg006NA222L-119V/PR8 (222L-119 V) virus after oseltamivir administration. \*P < 0.05. #P < 0.05. ##P < 0.05. ###P < 0.05.

had been reported that NA-I222K/R substitution of A (H7N9) made the virus more virulent (weight loss and survival rate) in mice but not in MDCK cells<sup>44</sup>, which was consistent with our study. It was suggested that NA I222L substitution made rg006NA222L-119V/PR8 virus more virulent in mice. Generally speaking, there was no significant difference in the survival day (10<sup>1</sup> TCID<sub>50</sub>–10<sup>6</sup> TCID<sub>50</sub>), lung/trachea virus load and lung pathological



**Figure 7.** Pathological changes of lung tissue of mice infected with H7N9/PR8 recombinant viruses treated with oseltamivir phosphate. The lung tissues of mice infected with H7N9/PR8 recombinant viruses were stained by hematoxylin and eosin ((A) HE  $\times 20$ ) and NP antigen ((B) IHC  $\times 20$ ) 4 days after infection. Ose (oseltamivir treatment group):  $2\text{MLD}_{50}$  rg006NA/PR8, 20 mg/kg/day, rg006NA119V/PR8, rg006NA222L/PR8 or rg006NA222L-119V/PR8 infection, oseltamivir phosphate by gavage from 0 to 4 dpi; PBS(control group):  $2\text{MLD}_{50}$  rg006NA/PR8, 20 mg/kg/day, rg006NA119V/PR8, rg006NA222L-119V/PR8 or rg006NA222L/PR8 infection, PBS by gavage from 0 to 4 dpi. Control group, PBS, 20 mg/kg/day oseltamivir phosphate by gavage from 0 to 4dpi.

changes among the four virus infection mice groups. The N9 E119V-I222L virus which had synergistic drug resistance effect did not seriously damage of its fitness in mice.

In terms of bio-safety and practical conditions, the recombinant viruses used in the mouse experiment were attenuated. Compared with their corresponding HPAI H7N9 viruses, the replication ability on MDCK cells of the attenuated H7N9/PR8 recombinant viruses decreased to some extent (data not shown). The pathogenicity of the H7N9/PR8 viruses was weaker than their corresponding HPAI H7N9 viruses in mice. This is one of the limitations of this study. However, the H7N9/PR8 recombinant viruses developed in this study could replicate in respiratory tract of C57 mice and lead to pneumonia, weight loss and even death, indicating the C57 mice infected with H7N9/PR8 recombinant viruses with reduced susceptibility to NAIs were feasible model for the study on the mechanism of HPAI H7N9 NAIs resistance and the preliminary selection of alternative drugs.

In summary, although NA I222L did not lead HPAI H7N9 virus to drug resistance itself, it could increase the resistance of HPAI H7N9 virus with NA E119V without severely impaired fitness *in vitro*. Consistent with results *in vitro*, substitutions of I222L and E119V in neuraminidase from HPAI H7N9 influenza virus exhibited a synergistic resistance effect to oseltamivir without significantly reduced pathogenicity in mice. Due to the good fitness of drug resistant strains of HPAI H7N9 virus, it is necessary to strengthen drug resistance surveillance, as well as research and application of new drugs.

## Materials and methods

All experiments including any relevant details were approved by designated institution and/or licensing committee, and all experiments were performed in accordance with the relevant guidelines.

**Generation of recombinant viruses.** The generation of HPAI H7N9 recombinant viruses was described in Tang et al.<sup>24</sup>. In short, HPAI H7N9 A/Guangdong/17SF006/2017 (abbreviated as 006) isolated from a human case was used as backbone virus. All eight gene segments of 006 strain were artificially synthesized (Sangon Biotech) and cloned into the pHW2000 vector. The NAIs sensitive HPAI H7N9 reassortant virus encoded 222I and 119E in the NA protein. A single-point mutation was introduced to convert 119E to 119V or 222I to 222L in NA. Then, in the 119V background, single-point mutations I222L in the NA gene were carried out. E119V or I222L substitutions were generated with the following primers:

NA E119V Forward, gtcgcatgaacatagggtactctgtgactaaacatc,  
 NA E119V Reverse, gatgttttagtacaagagtacccatgtttcatgac,  
 NA I222L Forward, acacatgggcccgaactactaagaacacagaa,  
 NA I222L Reverse, ttctgttcttagtaagttcgggccatgtg.

Mutations were introduced into the NA plasmid using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). HPAI H7N9 reassortment viruses were used to examine the effect of NA amino acid substitutions on NAIs susceptibility and viral replication efficiency *in vitro*.

Considering the bio-safety and actual conditions, attenuated H7N9 reassortment viruses were prepared to evaluate the pathogenicity and drug resistance in mice. The internal six genes of the attenuated virus were from A/PR/8/34 (H1N1). The HA gene was from 006strain after deletion of its highly pathogenic molecular markers (KRTA in 339–342 residue). The recombinant H7N9/PR8 attenuated virus was prepared by transfection of the above seven plasmids and 006 NA plasmids. HA 339–342KRTA deletion was generated with the following primers:

HAdel Forward, caaataggccttctcttgaacctcaggaacattc,  
 HAdel Reverse, gaatgttctgaggtccaagagaagagcctattg.

The recombinant virus was generated by reverse genetics. In general, the eight plasmids were co-transfected into 293T/MDCK co-cultured monolayer for 72 h<sup>45,46</sup>. Supernatants in culture flask were inoculated in embryonated eggs at 35 °C. Hemagglutination test was used for detection of positive viruses. Virus stocks were sequenced for verification, and virus titrations were determined with MDCK cells. The log<sub>10</sub> TCID<sub>50</sub>/ml was calculated by Reed and Muench method.

The recombinant H7N9/PR8 virus was evaluated as follows:

- (1) Virus sequencing: confirm whether each gene is correct and knock out of polybasic amino acids on HA.
- (2) Lethal dose of H7N9/PR8 recombinant virus on chicken embryo.
- (3) Trypsin dependent test: confirmed that the replication of recombinant H7N9/PR8 virus depends on TPCK trypsin.

**Cells and compounds.** The grown and maintainance of MDCK cells and 293 T cells were described before<sup>24</sup>. In short, cells were grown and maintained in Dulbecco's modified Eagle's medium (DMEM; Invitrogen) supplemented with 10% fetal bovine serum (FBS, Invitrogen), HEPES (10 mM, Invitrogen), penicillin (100 units/ml), and streptomycin (100 µg/ml, Invitrogen). The NA inhibitors used *in vitro* experiment were oseltamivir carboxylate (Hoffman-La Roche), zanamivir (GlaxoSmithKline), Peramivir (MCE company) and Laninamivir (MCE company). The pro-drug oseltamivir phosphate (oseltamivir) used in mice was purchased from MCE company. The NA inhibitors were prepared in sterile distilled water and stored in aliquots at – 20 °C.

**NA inhibition test.** Inhibition of NA enzyme activity of the 4 NA inhibitors was assessed in the fluorescence-based NA inhibition assay, using the NA-Fluor Influenza Neuraminidase Assay kit (Applied Biosystems, ThermoFisher) as previously described<sup>47</sup>. IC<sub>50</sub> values, defined as the concentration of drug required to reduce enzyme activity by 50%, were calculated using GraphPad prism5 software. Interpretation of IC<sub>50</sub> was performed using the WHO Antiviral Working Group (WHO-AVWG) criteria<sup>47–49</sup>: the testing virus was compared with the drug-sensitive reference virus, for influenza A viruses, a < tenfold increase in IC<sub>50</sub> represents normal inhibition, and a ten to 100-fold increase represents reduced inhibition, while a > 100-fold increase is highly reduced inhibition.

**Growth kinetics in MDCK cells.** The method of growth kinetics of HPAI H7N9 viruses in MDCK cells was described before<sup>24</sup>. Briefly speaking, MDCK cells were infected with the recombinant virus at an MOI of 0.001 at 37 °C 5% CO<sub>2</sub>. Cells were washed twice with PBS after 1 h of incubation, and infection medium containing TPCK-trypsin was added. At time points 0, 18, 24, 48, 72 and 96 h post-infection (hpi), supernatants were collected, and 3 biological repeats were set up for each sample. Viral titers were determined on MDCK cells.

**Pathogenicity in mice.** All mouse experiments were conducted after the approval of the Ethics Committee of the National Institute for Viral Disease Control and Prevention, China CDC (20191106039). For pathogenic study, specific-pathogen-free (SPF), female 8-week-old C57BL/6 mice were intranasal inoculated with 50 µl of 10<sup>1</sup>–10<sup>6</sup> TCID<sub>50</sub> recombinant H7N9/PR8 virus under isoflurane anaesthesia<sup>50</sup>. The weight change from 1 to 14 days post-infection (dpi) was calculated as a percentage of weight on 0 dpi (n = 5/group). Mice that showed severe disease and lost ≥ 20% of initial weight were euthanized. On 1, 3, 5, 7 and 14 dpi after inoculation, the lungs and trachea were removed from 3 mice of each group infected with 10<sup>4</sup>–10<sup>5</sup> TCID<sub>50</sub> virus, rinsed with sterile phosphate-buffered saline (PBS), homogenized, and resuspended in 1 ml of PBS. The suspensions were cleared by centrifugation at 3000×g for 20 min, and virus yield was determined by TCID<sub>50</sub> in MDCK cells. On 3dpi, Lungs of mice infected with 10<sup>4</sup>–10<sup>5</sup> TCID<sub>50</sub> virus (n = 3/group), were fixed in 10% paraformaldehyde and then for pathological study.

**Oseltamivir efficacy in mice.** SPF, female 8-week-old C57BL/6 mice were intranasal inoculated with 50 µl of two 50% mouse lethal doses (MLD<sub>50</sub>) of recombinant H7N9/PR8 viruses under isoflurane anaesthesia. Starting 0 dpi, mice in the drug treatment group were orally administered 100 µl oseltamivir at the dosage of 20 mg/kg/day BID (at 12 h intervals) for 5 days<sup>16</sup>. Untreated mice orally received 100 µl PBS twice daily for 5 days. Body weights and survival of infected mice were monitored for 14 days daily (n = 5/group). Mice that lost more than 20% of their initial weight were euthanized. The body weight change of mice was calculated and shown as a percentage of its initial weight. On 2, 4 and 6 dpi, the lungs were removed from 3 mice per group for viral load titration and pathological study.

**Lung histopathology and immunohistochemistry.** Pathological research methods were described in previous studies<sup>49</sup>. In short, the lung tissue of mice fixed with formalin was cut into sections and then stained with hematoxylin and eosin (H&E). The distribution of antigens (influenza A nucleoprotein) was studied by immunohistochemistry (IHC).

**Serologic tests.** Hemagglutination inhibition (HI) assay test was done to calculate the mouse infective dose of 50% animals (MID<sub>50</sub>)<sup>49</sup>. In short, at 14 dpi, serum samples were obtained from mice that survived from the pathogenic study. Sera were collected by retro-orbital bleed, treated with receptor-destroying enzyme for 18 h, and then heat-inactivated at 56 °C for 1 h, and tested by HI assay with 1% turkey red blood cells. HA titer ≥ 40 is positive; HA titer < 40 is negative.

**Crystal structure display of NA substitutions.** The existing NA protein crystal structure of A/Anhui/1/2013 H7N9 virus (PDB ID: 4MWJ)<sup>37</sup> in Protein Data Bank (PDB) was used, based on which a crystal structure model of the NA monomer was obtained. DeepViewv4.1.0 software was used to display and label drug resistance mutations.

**Statistical analysis.** NAIs susceptibility and viral replication were analysis by the GraphPad Prism 5.0 software. Student's t test was used to evaluate differences between two groups. ANOVA test and Kruskal–Wallis H test were used to evaluate differences among four groups. Cox regression was used to analyze hazard ratio by SPSS software. A P value of < 0.05 was considered significant.

**Biosafety.** All experiments involving HPAI H7N9 viruses were operated by qualified person in BSL-3 laboratory of National Institute for Viral Disease Control and Prevention, Chinese center for disease control and prevention.

**Statement of the ARRIVE guidelines.** We confirmed the study was carried out in compliance with the ARRIVE guidelines.

Received: 15 June 2020; Accepted: 29 July 2021

Published online: 11 August 2021

## References

- Zhang, F. *et al.* Human infections with recently-emerging highly pathogenic H7N9 avian influenza virus in China. *J. Infect.* **75**, 71–75. <https://doi.org/10.1016/j.jinf.2017.04.001> (2017).
- Yang, L. *et al.* Genesis and spread of newly emerged highly pathogenic H7N9 avian viruses in mainland China. *J. Virol.* <https://doi.org/10.1128/JVI.01277-17> (2017).
- Yu, D. *et al.* The re-emergence of highly pathogenic avian influenza H7N9 viruses in humans in mainland China, 2019. *Euro Surveill.* <https://doi.org/10.2807/1560-7917.ES.2019.24.21.1900273> (2019).
- Zhu, W. *et al.* Biological characterisation of the emerged highly pathogenic avian influenza (HPAI) A(H7N9) viruses in humans, in mainland China, 2016 to 2017. *Euro Surveill.* <https://doi.org/10.2807/1560-7917.ES.2017.22.19.30533> (2017).
- Yang, J.-R. & Liu, M.-T. Human infection caused by an avian influenza A (H7N9) virus with a polybasic cleavage site in Taiwan, 2017. *J. Formos. Med. Assoc.* **116**, 210–212. <https://doi.org/10.1016/j.jfma.2017.02.011> (2017).
- Zhou, L. *et al.* Preliminary Epidemiology of human infections with highly pathogenic avian influenza A(H7N9) virus, China, 2017. *Emerg. Infect. Dis.* **23**, 1355–1359. <https://doi.org/10.3201/eid2308.170640> (2017).
- Samson, M., Pizzorno, A., Abed, Y. & Boivin, G. Influenza virus resistance to neuraminidase inhibitors. *Antiviral Res.* **98**, 174–185. <https://doi.org/10.1016/j.antiviral.2013.03.014> (2013).
- Gao, R. *et al.* Human infection with a novel avian-origin influenza A (H7N9) virus. *N. Engl. J. Med.* **368**, 1888–1897. <https://doi.org/10.1056/NEJMoa1304459> (2013).
- Xie, J. *et al.* Epidemiological, clinical, and virologic features of two family clusters of avian influenza A (H7N9) virus infections in Southeast China. *Sci. Rep.* **7**, 1512. <https://doi.org/10.1038/s41598-017-01761-w> (2017).
- Li, Q. *et al.* Epidemiology of human infections with avian influenza A(H7N9) virus in China. *N. Engl. J. Med.* **370**, 520–532. <https://doi.org/10.1056/NEJMoa1304617> (2014).
- Du, Z. *et al.* Modeling mitigation of influenza epidemics by baloxavir. *Nat. Commun.* **11**, 2750. <https://doi.org/10.1038/s41467-020-16585-y> (2020).
- Hiroki, K. *et al.* Tolerability, and pharmacokinetics of the novel anti-influenza agent baloxavir marboxil in healthy adults phase I study findings. *Clin. Drug Investig.* **38**, 1189–1196. <https://doi.org/10.1007/s40261-018-0710-9> (2018).
- Adams, S. E. *et al.* Laninamivir-Interferon Lambda 1 Combination treatment promotes resistance by influenza A virus more rapidly than laninamivir alone. *Antimicrob. Agents Chemother.* **64**, e00301–00320. <https://doi.org/10.1128/AAC.00301-20> (2020).
- Agol, V. I. & Gmyl, A. P. Emergency services of viral RNAs: Repair and remodeling. *Microbiol. Mol. Biol. Rev.* <https://doi.org/10.1128/MMBR.00067-17> (2018).
- Vignuzzi, M., Stone, J. K., Arnold, J. J., Cameron, C. E. & Andino, R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. *Nature* **439**, 344–348. <https://doi.org/10.1038/nature04388> (2006).
- Baranovich, T. *et al.* The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome. *J. Infect. Dis.* **209**, 1343–1353. <https://doi.org/10.1093/infdis/jit554> (2014).
- Zhang, X. *et al.* Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui lineage) with R292K substitution. *Emerg. Microbes Infect.* **3**, e78. <https://doi.org/10.1038/emi.2014.80> (2014).
- Burnham, A. J. *et al.* Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: Underscoring the importance of E119A and H274Y. *Antimicrob. Agents Chemother.* **58**, 2718–2730. <https://doi.org/10.1128/AAC.02628-13> (2014).
- Colman, P. M., Varghese, J. N. & Laver, W. G. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. *Nature* **303**, 41–44. <https://doi.org/10.1038/303041a0> (1983).
- Song, M. S. *et al.* Unique Determinants of neuraminidase inhibitor resistance among N3, N7, and N9 avian influenza viruses. *J. Virol.* **89**, 10891–10900. <https://doi.org/10.1128/JVI.01514-15> (2015).
- Choi, W. S. *et al.* Screening for neuraminidase inhibitor resistance markers among avian influenza viruses of the N4, N5, N6, and N8 neuraminidase subtypes. *J. Virol.* <https://doi.org/10.1128/JVI.01580-17> (2018).
- Gubareva, L. V. *et al.* Drug susceptibility evaluation of an influenza A(H7N9) virus by analyzing recombinant neuraminidase proteins. *J. Infect. Dis.* **216**, S566–S574. <https://doi.org/10.1093/infdis/jiw625> (2017).
- Tang, J. *et al.* Profile and generation of reduced neuraminidase inhibitor susceptibility in highly pathogenic avian influenza H7N9 virus from human cases in Mainland of China, 2016–2019. *Virology* **549**, 77–84. <https://doi.org/10.1016/j.virol.2020.07.018> (2020).
- Tang, J. *et al.* Highly pathogenic avian influenza H7N9 viruses with reduced susceptibility to neuraminidase inhibitors showed comparable replication capacity to their sensitive counterparts. *Virology* **16**, 87. <https://doi.org/10.1186/s12985-019-1194-9> (2019).
- Centers for Disease Control & Prevention. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis—North Carolina, 2009. *Morb Mortal Wkly. Rep.* **58**, 969–972 (2009).
- Baz, M., Abed, Y., McDonald, J. & Boivin, G. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. *Clin. Infect. Dis.* **43**, 1555–1561. <https://doi.org/10.1086/508777> (2006).
- Colman, P. M., Hoyne, P. A. & Lawrence, M. C. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. *J. Virol.* **67**, 2972–2980 (1993).
- Colman, P. M. *et al.* The structure of a complex between influenza virus neuraminidase and an antibody. *Acta Crystallogr. A* **43**, C34–C35. <https://doi.org/10.1107/s0108767387084538> (1987).
- Kim, C. U. *et al.* Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. *J. Am. Chem. Soc.* **119**, 681–690. <https://doi.org/10.1021/ja963036t> (1997).
- Abed, Y., Nehme, B., Baz, M. & Boivin, G. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. *Antiviral Res.* **77**, 163–166. <https://doi.org/10.1016/j.antiviral.2007.08.008> (2008).
- Hurt, A. C., Holien, J. K. & Barr, I. G. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. *Antimicrob. Agents Chemother.* **53**, 4433–4440. <https://doi.org/10.1128/AAC.00334-09> (2009).
- Okomo-Adhiambo, M. *et al.* Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: Challenges in diagnosis of oseltamivir resistance. *Antimicrob. Agents Chemother.* **54**, 1834–1841. <https://doi.org/10.1128/AAC.01608-09> (2010).
- Richard, M. *et al.* Impact of influenza A virus neuraminidase mutations on the stability, activity, and sensibility of the neuraminidase to neuraminidase inhibitors. *J. Clin. Virol.* **41**, 20–24. <https://doi.org/10.1016/j.jcv.2007.10.021> (2008).
- Gaymard, A. *et al.* Impact on antiviral resistance of E119V, I222L and R292K substitutions in influenza A viruses bearing a group 2 neuraminidase (N2, N3, N6, N7 and N9). *J. Antimicrob. Chemother.* **71**, 3036–3045. <https://doi.org/10.1093/jac/dkw275> (2016).
- Hatakeyama, S. *et al.* Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. *JAMA* **297**, 1435–1442. <https://doi.org/10.1001/jama.297.13.1435> (2007).
- McKimm-Breschkin, J. L. *et al.* I222 Neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian Clade 2.1 highly pathogenic Avian Influenza A(H5N1) viruses. *PLoS ONE* **8**, e66105. <https://doi.org/10.1371/journal.pone.0066105> (2013).
- Wu, Y. *et al.* Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses. *Cell Res.* **23**, 1347–1355. <https://doi.org/10.1038/cr.2013.144> (2013).

38. Moscona, A. Medical management of influenza infection. *Annu. Rev. Med.* **59**, 397–413. <https://doi.org/10.1146/annurev.med.59.061506.213121> (2008).
39. von Itzstein, M. The war against influenza: Discovery and development of sialidase inhibitors. *Nat. Rev. Drug Discov.* **6**, 967–974. <https://doi.org/10.1038/nrd2400> (2007).
40. Chairat, K. *et al.* Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers. *Br. J. Clin. Pharmacol.* **81**, 1103–1112. <https://doi.org/10.1111/bcp.12892> (2016).
41. Lee, N. *et al.* A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza A and B infections. *Clin. Infect. Dis.* **57**, 1511–1519. <https://doi.org/10.1093/cid/cit597> (2013).
42. South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: Double blind randomised controlled trial. *BMJ* **346**, 3039. <https://doi.org/10.1136/bmj.f3039> (2013).
43. Ariano, R. E. *et al.* Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. *CMAJ* **182**, 357–363. <https://doi.org/10.1503/cmaj.092127> (2010).
44. Marjuki, H. *et al.* Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan. *J. Infect. Dis.* **15**, 249–257. <https://doi.org/10.1093/infdis/jiu447> (2015).
45. Fodor, E. *et al.* Rescue of influenza A virus from recombinant DNA. *J. Virol.* **73**, 9679–9682 (1999).
46. Hoffmann, E., Neumann, G., Kawaoka, Y., Hobom, G. & Webster, R. G. A DNA transfection system for generation of influenza A virus from eight plasmids. *Proc. Natl. Acad. Sci. U.S.A.* **97**, 6108–6113. <https://doi.org/10.1073/pnas.100133697> (2000).
47. Okomo-Adhiambo, M. *et al.* Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011–2012: Application of the WHO antiviral working group criteria. *Influenza Other Respir. Viruses* **8**, 258–265. <https://doi.org/10.1111/irv.12215> (2014).
48. Huang, W. *et al.* Characteristics of oseltamivir-resistant influenza A (H1N1) pdm09 virus during the 2013–2014 influenza season in Mainland China. *Virol. J.* **12**, 96. <https://doi.org/10.1186/s12985-015-0317-1> (2015).
49. WHO. *Meetings of the WHO Working Group on Surveillance of Influenza Antiviral Susceptibility—Geneva* (WHO, 2012).
50. Liu, S. *et al.* Substitution of D701N in the PB2 protein could enhance the viral replication and pathogenicity of Eurasian avian-like H1N1 swine influenza viruses. *Emerg. Microbes Infect.* **7**, 75. <https://doi.org/10.1038/s41426-018-0073-6> (2018).

## Acknowledgements

This work was supported by the National Major science and technology projects (2020ZX10001-016), National Key Research and Development Program of China (2016YFD0500208).

## Author contributions

D.W. and J.T. conceived and designed the study. J.T. wrote the main manuscript text. D.W. revised the manuscript. J.T., R.G., S.Z., C.X., J.L. and X.L. participated in the experiment and acquisition of data. D.W., L.L., Q.F., Z.F. and W.H. provided material or experience assistance. All authors read and approved the final manuscript.

## Competing interests

The authors declare no competing interests.

## Additional information

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1038/s41598-021-95771-4>.

**Correspondence** and requests for materials should be addressed to D.W.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021